Hem › Burkitts lymfom
Kliniska studier för Burkitts lymfom som rekryterar i USA
63 studier för Burkitts lymfom rekryterar deltagare vid platser över hela USA.
Städer med flest studier
- Houston, TX21 studier
- Milwaukee, WI16 studier
- Philadelphia, PA16 studier
- New York City, NY14 studier
- Chicago, IL14 studier
- Cincinnati, OH12 studier
- Atlanta, GA12 studier
- Seattle, WA11 studier
- Boston, MA10 studier
- Durham, NC10 studier
- Aurora, CO10 studier
- Los Angeles, CA10 studier
- Kansas City, MO10 studier
- Washington, DC9 studier
- Minneapolis, MN9 studier
- Orange, CA9 studier
- Baldwin Park, CA9 studier
- Buffalo, NY8 studier
- Portland, OR8 studier
- Columbus, OH8 studier
- San Francisco, CA8 studier
- Nashville, TN8 studier
- Baltimore, MD8 studier
- Ann Arbor, MI8 studier
- Tampa, FL7 studier
- Clifton, NJ7 studier
- Dallas, TX7 studier
- Providence, RI7 studier
- Salt Lake City, UT7 studier
- Grand Rapids, MI7 studier
- Cleveland, OH7 studier
- Richmond, VA7 studier
- Greenburgh, NY7 studier
- San Antonio, TX7 studier
- Oklahoma City, OK7 studier
- Birmingham, AL7 studier
- Jacksonville, FL7 studier
- The Bronx, NY6 studier
- Mountain View, CA6 studier
- New Haven, CT6 studier
Efter delstat
- Alabama7 studier
- Arizona7 studier
- Arkansas5 studier
- Colorado13 studier
- Connecticut7 studier
- Delaware7 studier
- District of Columbia5 studier
- Florida15 studier
- Georgia12 studier
- Hawaii5 studier
- Idaho6 studier
- Illinois14 studier
- Indiana6 studier
- Iowa7 studier
- Kalifornien20 studier
- Kansas6 studier
- Kentucky5 studier
- Louisiana4 studier
- Maine4 studier
- Maryland11 studier
- Massachusetts10 studier
- Michigan10 studier
- Minnesota10 studier
- Mississippi4 studier
- Missouri8 studier
- Nebraska5 studier
- Nevada6 studier
- New Hampshire4 studier
- New Jersey8 studier
- New Mexico3 studier
- New York20 studier
- North Carolina13 studier
- North Dakota5 studier
- Ohio17 studier
- Oklahoma7 studier
- Oregon8 studier
- Pennsylvania18 studier
- Rhode Island7 studier
- South Carolina5 studier
- South Dakota5 studier
- Tennessee10 studier
- Texas24 studier
- Utah7 studier
- Vermont3 studier
- Virginia7 studier
- Washington11 studier
- West Virginia3 studier
- Wisconsin17 studier
Nyligen uppdaterade studier
Officiell studietext (engelska)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekryterarFas 2
366 Days – 46 Years · Alla kön · Uppdaterad 2 okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RekryterarFas 3
Ålder 18 till 39 · Alla kön · Uppdaterad 2 okt. 2026 · NCT03150693Blinatumomab Consolidation in Real World
RekryterarObservationsstudieFriska volontärer välkomna
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekryterarObservationsstudie
Ålder 0 till 38 · Alla kön · Uppdaterad 1 okt. 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RekryterarFas 1/2
Ålder 3 till 39 · Alla kön · Uppdaterad 30 sep. 2026 · NCT05442515Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT03739814Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RekryterarFas 1/2
Ålder 18 till 120 · Alla kön · Uppdaterad 28 sep. 2026 · NCT03223610Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT06144606Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekryterarFas 2
365 Days · Alla kön · Uppdaterad 25 sep. 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 21 sep. 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
RekryterarFas 3
Ålder 1 och äldre · Alla kön · Uppdaterad 17 sep. 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekryterarFas 1/2
6 Months – 25 Years · Alla kön · Uppdaterad 17 sep. 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RekryterarFas 1
Ålder 0 till 18 · Alla kön · Uppdaterad 16 sep. 2026 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
RekryterarFas 1/2
31 Days – 30 Years · Alla kön · Uppdaterad 14 sep. 2026 · NCT04544592Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RekryterarFas 2
Ålder 1 till 30 · Alla kön · Uppdaterad 1 sep. 2026 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RekryterarFas 1
Ålder 18 till 120 · Alla kön · Uppdaterad 25 aug. 2026 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekryterarFas 3
365 Days – 25 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Rekryterar
Ålder 18 och äldre · Alla kön · Uppdaterad 19 aug. 2026 · NCT06710418Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RekryterarFas 2
Ålder 7 till 25 · Alla kön · Uppdaterad 19 aug. 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 19 aug. 2026 · NCT06137118AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 12 aug. 2026 · NCT06340737Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 10 aug. 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
RekryterarFas 2
Ålder 15 och äldre · Alla kön · Uppdaterad 10 aug. 2026 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekryterarFas 1/2
Ålder 13 till 90 · Alla kön · Uppdaterad 6 aug. 2026 · NCT06533579Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.